Read article – Diane Gilbert-Diamond, assistant professor of epidemiology and community and family medicine, is quoted about a recent study she led with other Dartmouth researchers about how prenatal exposure to arsenic harms the health of infants. The study results suggest even low levels of arsenic exposure during pregnancy may impact fetal growth, though this may be modified by the mother’s weight and the sex of the baby.

Read article – Quotes Samir Soneji, assistant professor of The Dartmouth Institute for Health Policy and Clinical Practice and lead study author of a new study that found teens may have easy access to e-cigarette marketing online even though U.S. regulations require tobacco websites to verify users are old enough to legally smoke.

Read article – Quotes Elliott Fisher, director of The Dartmouth Institute for Health Policy and Clinical Practice and professor of medicine and community and family medicine, about a recent study where researchers found that retail clinics—clinics inside drugstores and department stores—increase medical spending by attracting people who otherwise would have stayed home.

Read article – James Sargent, the Scott M. and Lisa G. Stuart Professor of Pediatric Oncology and professor of pediatrics and of community and family medicine, is quoted about how more is done to curtail junk-food advertising aimed at young people than to prevent them from viewing alcohol ads. “There’s very strong evidence that underage drinkers are not only exposed to the television advertising, but they also assimilate the messages,” says Sargent. “That process moves them forward in their drinking behavior.”

Read article – Lisa Schwartz, professor of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, is quoted about how two pharmaceutical companies—Johnson & Johnson and Bayer—and researchers from Duke University omitted critical laboratory data from a letter published in The New England Journal of Medicine in an effort to protect their blockbuster anticlotting drug. “It just feels like it’s a real ethical breach,” says Schwartz. “If you know the direct answer to this question, then how can you not provide it to be able to give insight?”

Read article – Continued coverage of comments by Lisa Schwartz and Steven Woloshin, both professors of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, from an editorial about their concerns regarding the drug  flibanserin, which was rejected twice by the FDA after findings of weak benefit and potentially serious side effects.